Aprea Therapeutics (APRE) Misses Q4 EPS by 49c
Tweet
Share
E-mailGet Alerts APRE Hot Sheet
Join SI Premium – FREE
Aprea Therapeutics (NASDAQ: APRE) reported Q4 EPS of ($0.49). Revenue for the quarter came in at $210 thousand.
For earnings history and earnings-related data on Aprea Therapeutics (APRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Evolv Technology adds 70 customers in Q2, expands bag screening
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
